-
Millennium Pharmaceuticals, Inc. v. Fresenius Kabi USA, LLC DC
- 1:19-cv-02252
- D. Del.
- Judge: Colm F. Connolly
- Filed: 12/10/2019
- Closed: 03/25/2020
- Latest Docket Entry: 03/25/2020
- PACER
- Docket updated daily
1
Plaintiff
2
Defendants
1
Accused
Product
2
Patents-in-Suit
107
Days in
Litigation
-
Millennium Pharmaceuticals, Inc. v. Fresenius Kabi USA, LLC DC
- 1:19-cv-02252
- D. Del.
- Judge: Colm F. Connolly
- Filed: 12/10/2019
- Closed: 03/25/2020
- Latest Docket Entry: 03/25/2020
- PACER
- Docket updated daily
Cause of Action
Infringement
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 20 |
The lyophilized compound D-mannitol N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronate.
|
Valid
Entry 18 |
| 31 |
The method of claim 23, wherein the compound of formula (1) is D-mannitol N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronate.
|
Valid
Entry 18 |
| 49 |
A lyophilized cake comprising the compound of claim 20.
|
Valid
Entry 18 |
| 53 |
The method of claim 31 further comprising (c) reconstituting the lyophilized mixture with a pharmaceutically-acceptable carrier.
|
Valid
Entry 18 |
-
Infringement
Fresenius KABI USA LLC
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| generic version of Bortezomib for injection 3.5 mg/vial | US 6,713,446 B2 |
20, 31, 49, 53
|
Infringement
Entry 18
|
